SCHEMBL420252

SCHEMBL420252

COC(=O)c1cc(Cl)ccc1NC(=O)c1cc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.72
ALDH1A1 P00352 4/20 0.72
KDM4E B2RXH2 3/20 0.65
GAA P10253 1/20 0.65
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
GFER P55789 1/20 0.64
CYP3A4 P08684 3/20 0.59
NPSR1 Q6W5P4 2/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
CYP1A2 P05177 1/20 0.58
MAPT P10636 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.57
PTGER4 P35408 1/20 0.56
LMNA P02545 1/20 0.56
STAT3 P40763 1/20 0.56
TACR3 P29371 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419079 0.88 MEN1 (0.74) HPGDALDH1A1KDM4EGAAMEN1
SCHEMBL9059538 0.88 MEN1 (0.78) HPGDALDH1A1KDM4EMEN1KMT2A
SCHEMBL418857 0.86 MEN1 (0.65) HPGDALDH1A1KDM4EGAAMEN1
SCHEMBL17923184 0.83 MAPT (0.74) HPGDALDH1A1KDM4EGAAMEN1
SCHEMBL18313926 0.82 MEN1 (0.65) HPGDALDH1A1KDM4EGAAMEN1
SCHEMBL420688 0.82 SLC6A4 (0.62) HPGDALDH1A1KDM4EGAANPSR1
SCHEMBL16098680 0.82 PLA2G2A (0.67) HPGDALDH1A1KDM4EGAAMEN1
SCHEMBL2576382 0.81 KDM4E (0.76) HPGDALDH1A1KDM4EGAAMEN1
SCHEMBL10758450 0.81 TACR3 (0.67) HPGDALDH1A1KDM4EGAAMEN1
SCHEMBL27951590 0.81 PLA2G2A (0.80) HPGDALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 HPGD 904/4885ALDH1A1 1450/4885KDM4E 4490/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 HPGD 904/4885ALDH1A1 1450/4885KDM4E 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.